148 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
in Earlier-Line Multiple Myeloma and Breyanzi in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma and Positive Proof of Concept for Opdualag … with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
indication to include the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who
8-K
EX-99.1
c76gub4om
8 Jan 24
Regulation FD Disclosure
10:29am
8-K
EX-99.1
g6g1pu83588
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.1
dy7xopqqzsd8nfqj
27 Apr 23
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
7:45am
8-K
EX-99.1
xhk1akly
10 Jan 22
Regulation FD Disclosure
6:59am
8-K
EX-99.1
31sw7r88
16 Nov 21
Regulation FD Disclosure
9:20am
8-K
EX-99.1
m8taodnw8mb
28 Jul 21
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
7:33am